|
Aug 26
|
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
|
|
Jul 25
|
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
|
|
Jul 10
|
Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)
|
|
Jun 20
|
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
|
|
Jun 18
|
Cellectis (CLLS) Upgraded to Buy: Here's Why
|
|
Jun 18
|
After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)
|
|
Jun 4
|
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
|
|
May 29
|
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
|
|
Jan 16
|
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
|
|
Dec 22
|
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
|
|
Nov 8
|
Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript
|
|
Nov 6
|
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
|
|
Jul 5
|
Monthly information on share capital and company voting rights
|